Microchip Capillary Electrophoresis Assay Buffer Chemistry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Microchip Capillary Electrophoresis (MCE) assays in quality control laboratories face challenges with assay interferences and the detection of impurities in protein drug products, particularly in biopharmaceuticals, which can lead to invalid test results and instrument-related issues.
Innovation Solution
Development of MCE assays and reagents that include non-reducing and reducing buffers with specific alkylating agents and lithium dodecyl sulfate, along with detectable labels, to denature protein samples and separate impurities on a microchip capillary electrophoresis system, producing an electropherogram for purity and impurity analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MCE assays are used for protein drug product analysis, then the analysis can be performed with standard reagents, but assay interferences occur and impurity detection is compromised
Solution Approach 1:
The patent modifies the chemical composition parameters of the electrophoresis buffer by incorporating specific reducing agents (beta-mercaptoethanol, dithiothreitol, tris(2-carboxyethyl)phosphine) and alkylating agents (iodoacetamide, iodoacetic acid, N-ethylmaleimide) at controlled concentrations. These parameter changes in the buffer chemistry eliminate assay interferences and improve impurity detection reliability without compromising the overall assay performance
2Measurement precision
If standard electrophoresis buffers are used, then the assay procedure is simple, but detection of impurities is insufficient
Solution Approach 1:
The patent applies preliminary chemical treatment to the protein sample by incorporating reducing agents that break disulfide bonds and alkylating agents that prevent reoxidation before the electrophoresis separation. This preliminary action ensures complete denaturation and prevents artifact formation during analysis, thereby improving impurity detection precision while maintaining a relatively simple overall procedure
3Manufacturing precision
If conventional buffers without reducing agents are used, then the buffer composition is simple, but protein aggregates and multimers are not properly separated
Solution Approach 1:
The patent changes the oxidation state parameter of the buffer system by adding reducing agents (beta-mercaptoethanol, dithiothreitol, or tris(2-carboxyethyl)phosphine) at specific concentrations (e.g., 5-50 mM beta-mercaptoethanol, 1-10 mM dithiothreitol, or 0.1-5 mM tris(2-carboxyethyl)phosphine). This parameter change enables proper separation of protein aggregates and multimers by breaking disulfide crosslinks, achieving manufacturing precision in separation while controlling buffer component complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution significantly reduces assay interferences and improves the detection of impurities in protein drug products, enhancing the reliability of quality control analyses by providing clear electropherograms that identify protein drug products and contaminants, thus ensuring higher analytical quality and reproducibility.
Implementation Method 1
to denature protein samples and separate impurities on a microchip capillary electrophoresis system
Implementation Method 2
separate impurities on a microchip capillary electrophoresis system
Implementation Method 3
Microchip Capillary Electrophoresis (MCE) allows for dramatically reduced sample analysis times
Implementation Method 4
non-reducing aqueous electrophoresis sample buffer containing an alkylating agent such as 2-iodoacetamide (IAM), iodoacetic acid (IAA), or N-ethylmaleimide (NEM)
Data Source
AI summary
Microchip Capillary Electrophoresis (MCE) assays and reagents to assess purity and to identify impurities in protein drug product samples are provided. Methods for analyzing analytes in a protein drug sample are provided.